Halozyme Therapeutics, Inc.HALONASDAQ
Loading
Operating Income ScalingExpanding
Percentile Rank100
3Y CAGR+45.0%
5Y CAGR+41.4%
Studio
Year-over-Year Change

Profit from core business operations before interest and taxes

3Y CAGR
+45.0%/yr
Annual compound
5Y CAGR
+41.4%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
5.7x
Strong expansion
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$816.29M+48.0%
2024$551.48M+63.4%
2023$337.57M+26.2%
2022$267.53M-3.0%
2021$275.90M+91.3%
2020$144.25M+313.4%
2019$-67.61M+2.5%
2018$-69.33M-185.6%
2017$81.00M+197.3%
2016$-83.21M-